<DOC>
	<DOCNO>NCT01398475</DOCNO>
	<brief_summary>The purpose trial ass effect three formulation relative bioavailability LY3009104 . Subjects receive single dose LY3009104 4 separate occasion without food . Safety evaluation serial Pharmacokinetic ( PK ) sample collect treatment period . Approximately 5-7 day washout period treatment follow-up visit occur approximately 5 7 day last dose study drug .</brief_summary>
	<brief_title>A Relative Bioavailability Food Effect Study New Formulations</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Overtly healthy male female determine medical history physical examination Have body mass index ( BMI ) 18.5 29.9 kg/m^2 , inclusive , screen Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have normal blood pressure pulse rate determine investigator Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Male Subjects : Agree use two form highly effective method birth control ( oral , injectable , implanted hormonal contraceptive ; condom spermicidal foam/gel/film/cream/suppository ; occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ; intrauterine device ; intrauterine system , example , progestin release coil ; vasectomise male ( appropriate postvasectomy documentation absence sperm ejaculate ) ) female partner childbearing potential study least 3 month follow last dose study drug Female subject : Are woman nonchildbearing potential , define : woman Mayer Rokitansky Kuster Hauser Syndrome ( also refer Clinical Absence Uterus Vagina ) , woman surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) , woman great 60 year age , woman great 40 less 60 year age cessation menses least 12 month folliclestimulating hormone ( FSH ) test confirm nonchildbearing potential ( FSH ≥40 mIU/mL ) Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product , concurrently enrol type medical research judge scientifically medically compatible study Have history adverse drug reaction `` drug allergy '' 3 type systemically administer medication ( penicillin cephalosporin may consider 1 type medication purpose ) Are person previously receive investigational product study , complete withdrawn study study investigate LY3009104 Have abnormality 12lead Electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Current recent history ( &lt; 30 day prior screen and/or &lt; 45 day prior Checkin ) clinically significant bacterial , fungal , parasitic , viral ( include rhinopharyngitis ) , mycobacterial infection Have ANC less 2000 cell/μL . For abnormal value , single repeat allow Have history , current , cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Regularly use know drug abuse Have symptomatic herpes zoster herpes simplex infection within 90 day prior first dose Have expose live vaccine within 12 week prior first dose expect need/receive live vaccine ( include herpes zoster vaccination ) course study Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Intend use overthecounter prescription medication herbal supplement within 14 day prior dose study Intend use vitamins mineral supplement within 2 day prior dose study Have donate blood 450 mL within previous 3 month Have consume grapefruit , starfruit , pomelo , product contain fruit , 7 day prior first dose study Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop alcohol consumption 48 hour prior admission period 48 hour PK sample collect ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Have use tobaccocontaining nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>